Skip to content

Women's Input on Sexual Health

K24: Advancing Reproductive Health: Women's Input on Sexual Health (Project WISH)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02057419
Acronym
WISH
Enrollment
8
Registered
2014-02-07
Start date
2014-04-14
Completion date
2018-03-31
Last updated
2025-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intravaginal Ring Use

Keywords

contraception, contraceptive methods, user experience

Brief summary

The purpose of this study is to answer the following question: How do user sensory perceptions and experiences (USPEs) for IVRS differ between initial and continued use and how can this knowledge help product developers better understand how to design new IVR products and develop behavioral (or point-of-care) interventions to optimize use?

Detailed description

Background: Sexual and reproductive health (SRH) is a global public health priority. Providing efficacious SRH technologies that have the greatest likelihood of use will have the greatest impact on women's health. Critical to use is acceptability. However, current conceptualizations of adherence and acceptability fail to fully articulate and account for the user experience. Given the recent development of various IVR technologies and the potential for multipurpose technologies, the impact on global public health would be far-reaching, affecting reproductive health in women and men: decreasing STI incidence, minimizing unplanned pregnancies, and decreasing morbidity and mortality due to a range of other reproductive health conditions. Condition: Participants will use an IVR for a period of three months and report sensory perceptions and use experiences. Methodology and Data Collection: Volunteers (N\ 6-10) will first be screened for the study using a brief questionnaire. Those who are interested in contraception and are eligible based on their responses to the prescreen will then complete a clinical screening visit and pregnancy test. Once enrolled participants will complete a survey that asks questions about demographics and sexual and reproductive history. During the course of the study, participants will evaluate their use of an IVR. IVRs will be used for three consecutive months. They will be given a three-month supply of the product at the beginning of the use period. About once a month, each participant will be required to complete a web survey about their experience with the study product. All participants complete a final survey that will ask about their experiences with the study product.

Interventions

None listed

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
The Miriam Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* are between the ages of 18 and 45 at prescreening, * report vaginal sex with a man in the past month at prescreening, * are not pregnant (self-report, confirmed at V1, V2, and V3 by urine HcG test) and report no intention to become pregnant during the course of the study, * report negative or unknown HIV status, * report a need for contraceptive products and * are willing and able to provide informed consent.

Exclusion criteria

* self-report pregnancy, have a positive urine pregnancy test at Visits 1, 2, or 3, or intend to become pregnant during the course of the study, * self-report breast feeding, * self-report a vaginal delivery or other reproductive surgical procedure in the past 30 days, * self-report being HIV-positive, * self-report being diagnosed with or having an active sexually transmitted infection (STI) in the past 12 months, * self-report an allergy or sensitivity to any of the study products, * do not have a cell phone or internet access, * are unable or unwilling to give informed consent, or * have any condition that, in the opinion of the study clinician(s) or principle investigator, would compromise the participant's ability to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
USPE Scale ScoresUp to 3 monthsUser sensory perceptions and experiences (USPEs) with the IVR will be captured approximately monthly over a 90 day use period. USPE Sum of averaged item means/# items (min:max 1:5); 1=Do not agree at all;2=Agree a little;3=Agree somewhat;4=Agree a lot;5=Agree completely. Product: IVR USPE Scales: Initial Penetration and First Strokes: Smoothness/lubricity; Awareness: Feel (not) intravaginally during sex; Discharge Look: Appearance of discharge; Discharge: Sensations of discharge during and after sex inside and outside body; Pleasure: Participant and partner's stimulation A higher score indicates greater agreement with subscale characteristics being reported on.

Countries

United States

Participant flow

Recruitment details

Recruited (RI, MA USA) via call-lists, flyers, ads, internet/social media, clinics, CBOs, word-of-mouth.

Participants by arm

ArmCount
Intravaginal Ring Users
Use IVR for 3-month period and report user sensory perceptions and experiences.
8
Total8

Baseline characteristics

CharacteristicIntravaginal Ring Users
Age, Customized
18-29
6 Participants
Age, Customized
30-45
2 Participants
Health Insurance Coverage
Another kind of health care insurance or health coverage plan_Parents' Insurance
1 Participants
Health Insurance Coverage
Covered by the Indian Health Service
0 Participants
Health Insurance Coverage
Covered by VA healthcare
0 Participants
Health Insurance Coverage
Currently do not have health insurance
2 Participants
Health Insurance Coverage
Medicaid, medical assistance, or other kind of government assistance plan
0 Participants
Health Insurance Coverage
Medicare due to a disability
0 Participants
Health Insurance Coverage
Purchased directly from an insurance company
1 Participants
Health Insurance Coverage
Through a current or former employer or union
4 Participants
Health Insurance Coverage
TRICARE or other military health care
0 Participants
Marital Status
Divorced
1 Participants
Marital Status
Married
0 Participants
Marital Status
Never Married
7 Participants
Marital Status
Separated
0 Participants
Marital Status
Widowed
0 Participants
Race/Ethnicity, Customized
American Indian or Alaska Native
0 Participants
Race/Ethnicity, Customized
Asian
0 Participants
Race/Ethnicity, Customized
Black or African American
0 Participants
Race/Ethnicity, Customized
Latina or Hispanic
2 Participants
Race/Ethnicity, Customized
More than one race
0 Participants
Race/Ethnicity, Customized
White
6 Participants
Region of Enrollment
United States
8 Participants
Sex/Gender, Customized
Female
8 participants
Typical Tampon Use
No
3 Participants
Typical Tampon Use
Yes
5 Participants
Yearly Income
$15,000 to $36,000 a year
6 Participants
Yearly Income
$36,000 or more a year
2 Participants
Yearly Income
Less than $15,000 a year
0 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 8
other
Total, other adverse events
2 / 8
serious
Total, serious adverse events
0 / 8

Outcome results

Primary

USPE Scale Scores

User sensory perceptions and experiences (USPEs) with the IVR will be captured approximately monthly over a 90 day use period. USPE Sum of averaged item means/# items (min:max 1:5); 1=Do not agree at all;2=Agree a little;3=Agree somewhat;4=Agree a lot;5=Agree completely. Product: IVR USPE Scales: Initial Penetration and First Strokes: Smoothness/lubricity; Awareness: Feel (not) intravaginally during sex; Discharge Look: Appearance of discharge; Discharge: Sensations of discharge during and after sex inside and outside body; Pleasure: Participant and partner's stimulation A higher score indicates greater agreement with subscale characteristics being reported on.

Time frame: Up to 3 months

ArmMeasureGroupValue (MEAN)Dispersion
Intravaginal Ring UsersUSPE Scale ScoresInitial Penetration & First Strokes (Month 1 IVR)3.73 score on a scaleStandard Deviation 1.55
Intravaginal Ring UsersUSPE Scale ScoresInitial Penetration & First Strokes (Month 3 IVR)3.63 score on a scaleStandard Deviation 1.21
Intravaginal Ring UsersUSPE Scale ScoresDischarge (Month 1 IVR)1.85 score on a scaleStandard Deviation 1.41
Intravaginal Ring UsersUSPE Scale ScoresDischarge (Month 3 IVR)2.02 score on a scaleStandard Deviation 1.49
Intravaginal Ring UsersUSPE Scale ScoresDischarge Look (Month 1 IVR)3.13 score on a scaleStandard Deviation 1.58
Intravaginal Ring UsersUSPE Scale ScoresDischarge Look (Month 3 IVR)3.07 score on a scaleStandard Deviation 1.59
Intravaginal Ring UsersUSPE Scale ScoresAwareness (Month 1 IVR)1.84 score on a scaleStandard Deviation 0.86
Intravaginal Ring UsersUSPE Scale ScoresAwareness (Month 3 IVR)1.82 score on a scaleStandard Deviation 1.02
Intravaginal Ring UsersUSPE Scale ScoresPleasure (Month 1 IVR)1.63 score on a scaleStandard Deviation 0.63
Intravaginal Ring UsersUSPE Scale ScoresPleasure (Month 3 IVR)2.81 score on a scaleStandard Deviation 1.12

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026